These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36306151)

  • 1. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
    Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
    Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Nieuwdorp M; Groen AK; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Dec; 18(12):1217-1225. PubMed ID: 27451030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
    Kim SH; Liu A; Ariel D; Abbasi F; Lamendola C; Grove K; Tomasso V; Reaven G
    Diabetologia; 2014 Mar; 57(3):455-62. PubMed ID: 24326527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial.
    Ahmad E; Waller HL; Sargeant JA; Webb MA; Htike ZZ; McCann GP; Gulsin G; Khunti K; Yates T; Henson J; Davies MJ; Webb DR
    Diabetes Obes Metab; 2021 Jun; 23(6):1409-1414. PubMed ID: 33565691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia.
    Mondragon A; Davidsson D; Kyriakoudi S; Bertling A; Gomes-Faria R; Cohen P; Rothery S; Chabosseau P; Rutter GA; da Silva Xavier G
    PLoS One; 2014; 9(8):e104873. PubMed ID: 25119717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
    Smits MM; Fluitman KS; Herrema H; Davids M; Kramer MHH; Groen AK; Belzer C; de Vos WM; Cahen DL; Nieuwdorp M; van Raalte DH
    Diabetes Metab; 2021 Sep; 47(5):101223. PubMed ID: 33429063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, open-label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.
    Webb DR; Htike ZZ; Swarbrick DJ; Brady EM; Gray LJ; Biglands J; Gulsin GS; Henson J; Khunti K; McCann GP; Waller HL; Webb MA; Sargeant JA; Yates T; Zaccardi F; Davies MJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1187-1196. PubMed ID: 32157772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of liraglutide on dietary lipid-induced insulin resistance in humans.
    Koska J; Lopez L; D'Souza K; Osredkar T; Deer J; Kurtz J; Salbe AD; Harman SM; Reaven PD
    Diabetes Obes Metab; 2018 Jan; 20(1):69-76. PubMed ID: 28605158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pieters-van den Bos IC; Vendrik KE; Hoekstra T; Bruno MJ; Diamant M; van Raalte DH; Cahen DL
    Diabetes Care; 2017 Mar; 40(3):301-308. PubMed ID: 27998910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Tonneijck L; Smits MM; Muskiet MH; Hoekstra T; Kramer MH; Danser AH; Ter Wee PM; Diamant M; Joles JA; van Raalte DH
    Diabetes Care; 2016 Nov; 39(11):2042-2050. PubMed ID: 27585605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.
    Foghsgaard S; Vedtofte L; Andersen ES; Bahne E; Andreasen C; Sørensen AL; Forman JL; Mathiesen ER; Svare JA; Clausen TD; Damm P; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2024 Jan; 26(1):201-214. PubMed ID: 37846555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
    Ferjan S; Janez A; Jensterle M
    Metab Syndr Relat Disord; 2017 Dec; 15(10):515-520. PubMed ID: 29064743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.